SciSparc Ltd. (SPRC) carries a Roarable Rating of D+ (Sell) with 55/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, SciSparc Ltd. (NASDAQ: SPRC) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 55/100 at a spot price of $0.68 (-5.05% 1D, market cap $1.5M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, SPRC ranks #236 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SPRC carries a Roarable D+ (55/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, GNPX (Genprex Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $1.7M) and OGEN (Oragenics Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $1.7M). Among the 5-stock peer group, SPRC leads on earnings multiple (N/A) while GNPX leads on capital efficiency (-35.0% ROIC).
For SciSparc Ltd. (SPRC), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #236 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
SEC XBRL Trailing 12 Months: 0% FCF Margin ($41.0K FCF) & 52% Gross Margin
Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment
Even with a 55/100 (D+) score, SPRC faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Company executives have done more routine share selling than personal cash buying lately.
Sensitive to high interest rates and tighter Federal Reserve market liquidity.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($4.17) or 200D SMA ($5.59) invalidates the momentum regime and cuts Target Base ($0.67) toward Bear Floor ($0.52).
SciSparc Ltd. (SPRC) dropped -5.05% to $0.68, trading at 2% of its 52-week range ($0.6 – $30.63). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
Gainers Axogen (NASDAQ:AXGN) stock rose 17.7% to $44.1 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.1 billion. As per the news, the Q3 earnings report came out today.
Oct. 27, 2026 U.S. top movers: BRAI led gainers at 73.58%, while DVLT led losers at -49.02%, ranked by percentage change.
A look at the biggest US stock movers on October 27, 2026, including the top percentage gainers and decliners with prices and context.
Today's gap stocks include gap-up leaders OPENZ, NEXR and MFIC, and gap-down movers DVLT, SPRC and ARTV, with gap sizes and session moves.
Premarket movers ahead of the US open: BRAI, OPENZ, NEXR, XXII and AUROW among top gainers, while DVLT, SPRC, ARTV and ACTU lead declines.
Gainers Kiniksa Pharmaceuticals (NASDAQ:KNSA) shares rose 23.1% to $89.86 during Tuesday's regular session. The market value of their outstanding shares is at $5.6 billion. As per the press release, Q3 earnings
U.S. stocks climbed Tuesday, led by the Nasdaq and tech shares. Coca-Cola beat Q3 estimates and raised guidance, while AI OKTO surged 74%.
Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 14.6% to $3.3 during Tuesday's pre-market session. The company's market cap stands at $14.4 million. Pomdoctor (NASDAQ:POM) stock moved
Celestica jumps 16.4% after beating Q3 FY26 estimates and raising guidance; 22nd Century leads premarket gainers at 69.8%.
After-hours movers: SNTI +54.25%, BRAI +29.25%, CLS +17.17%, SPRC -26.67%, DVLT -22.44% and ONCO -21.70%; CLS, JBLU, WHR and others reported results.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on SPRC today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for SPRC. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, SciSparc Ltd. (SPRC) ranks #236 by composite RQD confidence (55/100, grade D+) and #1010 by equity capitalization ($1.5M). Within this direct 5-issuer industry benchmark cohort, SPRC leads on earnings valuation at N/A trailing P/E, while GNPX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. PPBT currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with SPRC at 55/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| SPRC
ACTIVE
SciSparc Ltd. | D+ | 55/100 | — | — | — | -5.05% | $1.5M | Benchmark Subject |
| GNPX Genprex Inc. | D | 47/100 | — | — | -35.0% | +9.80% | $1.7M | /gnpx-vs-sprc → |
| OGEN Oragenics Inc. | D | 44/100 | — | — | -35.0% | -0.05% | $1.7M | /ogen-vs-sprc → |
| ARTL Artelo Biosciences Inc. | D- | 41/100 | — | — | -35.0% | -3.90% | $1.3M | /artl-vs-sprc → |
| PPBT Purple Biotech Ltd. | C- | 61/100 | — | — | — | +7.34% | $1.8M | /ppbt-vs-sprc → |
SciSparc Ltd. (SPRC) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $1.5M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
As of 2026-11-02, SciSparc Ltd. (NASDAQ: SPRC) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 55/100 at a spot price of $0.68 (-5.05% 1D, market cap $1.5M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, SPRC ranks #236 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SPRC carries a Roarable D+ (55/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, GNPX (Genprex Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $1.7M) and OGEN (Oragenics Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $1.7M). Among the 5-stock peer group, SPRC leads on earnings multiple (N/A) while GNPX leads on capital efficiency (-35.0% ROIC).
For SciSparc Ltd. (SPRC), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #236 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
SPRC last traded at $0.68 (-5.05% on volume of 378,106 shares), positioning the stock -83.69% below its 50-day simple moving average ($4.17) and -87.84% below its 200-day simple moving average ($5.59). Across its 52-week range of $0.60 to $30.63, SPRC sits at the 0.3% percentile with a 14-day RSI of 16.9 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.77).
Why SPRC Stock dropped -5.05% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).